Momelotinib: second-line treatment for myelofibrosis with anemia

被引：0
|
作者：
Lauren, Barette
机构：
来源：
HEMATOLOGIE | 2023年 / 29卷 / 05期
关键词：
RUXOLITINIB;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：267 / 269
页数：3
相关论文
共 50 条
  • [41] Second-line treatment with Topotecan in ovarian cancer
    Morales, S
    Balil, A
    Salud, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S87 - S87
  • [42] Escitalopram versus SNRIs as second-line treatment
    Lam, R. W.
    Lonn, S. Larsson
    Despiegel, N.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2009, 13 : 35 - 36
  • [43] Second-line systemic treatment for advanced cholangiocarcinoma
    Rogers, Jane E.
    Law, Lindsey
    Nguyen, Van D.
    Qiao, Wei
    Javle, Milind M.
    Kaseb, Ahmed
    Shroff, Rachna T.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (06) : 408 - 413
  • [44] Second-line treatment of postpartum haemorrhage (PPH)
    W. Rath
    A. Hackethal
    M. K. Bohlmann
    [J]. Archives of Gynecology and Obstetrics, 2012, 286 : 549 - 561
  • [45] Sirolimus as a second-line treatment for Graves' orbitopathy
    Lanzolla, G.
    Maglionico, M. N.
    Comi, S.
    Menconi, F.
    Piaggi, P.
    Posarelli, C.
    Figus, M.
    Marcocci, C.
    Marino, M.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (11) : 2171 - 2180
  • [46] Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia
    Winton, Elliott F.
    Kota, Vamsi
    [J]. FUTURE ONCOLOGY, 2017, 13 (05) : 395 - 407
  • [47] Myelofibrosis New Treatment Option with JAK2 Inhibitor Inrebic® (Fedratinib) in First- and Second-Line Setting
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (09) : 504 - 506
  • [48] Second-line drugs
    Weintraub, M
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (07): : 409 - 410
  • [49] New perspectives in the second-line treatment of NSCLC with pemetrexed
    Vansteenkiste, J.
    [J]. LUNG CANCER, 2006, 52 : S29 - S30
  • [50] Regorafenib promising second-line treatment in hepatocellular carcinoma
    不详
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (08) : 446 - 446
12345